Physician Assistant Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

Melanie McCoy

Physician Assistant Long Beach, MS Physician Assistant

NPI 1831703958 CMS profile 8797000

202 Joyce Ave, Long Beach, MS 39560

Open in the dashboard

General payments

$1,857

72 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Melanie McCoy of Long Beach, MS is reported in the CMS Open Payments database as having received $1,857 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $827 35
2021 General $1,030 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melanie McCoy
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Melanie McCoy were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Melanie McCoy Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,030 $132 $37–$438 $132
2022 $827 $155 $48–$522 $149
2023 $0 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. AstraZeneca Pharmaceuticals LP $829 22 payments
  2. Novo Nordisk Inc $394 18 payments
  3. AbbVie, Inc. $172 9 payments
  4. Amgen Inc. $145 3 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $77 5 payments
  6. Lilly USA, LLC $54 4 payments
  7. Hologic, LLC $41 2 payments
  8. Merck Sharp & Dohme Corporation $31 2 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $22 1 payment
  10. Grifols USA, LLC $21 1 payment
  11. Other $70 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Food and Beverage $1,845 71 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2022
  1. FARXIGA $403 15 payments
  2. RYBELSUS $380 17 payments
  3. BREZTRI $289 3 payments
  4. Ozempic $269 17 payments
  5. FASENRA $202 5 payments
  6. Otezla $140 2 payments
  7. VRAYLAR $94 5 payments
  8. UBRELVY $78 4 payments
  9. Kerendia $77 5 payments
  10. TRULICITY $42 3 payments
  11. Other $458 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

1,350

Median for Physician Assistant: 241

Drug cost

$67,558

Median for Physician Assistant: $4,110

Branded share of claims

11.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 15 $30,802
Xarelto Rivaroxaban Brand 13 $20,209
Mirtazapine Generic 17 $1,315
Omeprazole Generic 57 $1,085
Gabapentin Generic 42 $1,014
Levothyroxine Sodium Generic 130 $842
Atorvastatin Calcium Generic 83 $806
Losartan Potassium Generic 73 $804
Albuterol Sulfate Hfa Albuterol Sulfate Brand 35 $702
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $598

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$10,506

Of which drugs: $1,375

Medicare patients

76

Average age 76

Services billed

243

54 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 47%
Osteoporosis 34%
Ischemic heart disease 30%
Depression 26%
Diabetes 22%
Chronic kidney disease 20%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $982

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record